UNSPSC 51141526: Primidone

This classification denotes a barbiturate and anticonvulsant agent with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13AFD7670Q, chemically known as 4,6(1h,5h)-pyrimidinedione, 5-ethyldihydro-5-phenyl- but generally known as primidone, which bears US NIH Compound Identifier 4909. European Medicines Agency schedules Primidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10045MIG.

UNSPSC 51141526 Primidone is a Commodity code that nominally describes a specific anticonvulsant medication, but recent state and local solicitations tagged under this code show a much broader pharmaceutical procurement pattern spanning naloxone, safe drug deactivation systems, and multi-source generic pharmaceuticals with over-the-counter products. State and local government bodies purchasing under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves bulk procurement of medications and health-related products for distribution through established supply chains, including requirements for compliance with cGMP, the Drug Supply Chain Security Act, FDA approval, and delivery through authorized wholesalers or to designated health facilities.

Recent activity spans Florida, Texas, and Minnesota through multiple issuing bodies. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effective date, requiring vendors to work through three authorized wholesalers and meet detailed product specification and pricing documentation requirements.